Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Accelerated cartilage regeneration via chondrocyte metabolic reprogramming using nano-steroid-conjugated mesenchymal stem cells in osteoarthritis

Lee JY., Park JY., Kwon IA., Lim SH., Kim KB., Park JY.

Animal Study on Osteoarthritis, Cartilage Damage, Chronic Inflammation, Immune Modulation, published in Theranostics (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Theranostics (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41356803
PMCID
PMC12675149
DOI
10.7150/thno.120765

Abstract (original English)

Background: Osteoarthritis (OA) is a prevalent and debilitating chronic disease for which there are currently no approved disease-modifying osteoarthritis drugs (DMOADs). While mesenchymal stem cells (MSCs) have emerged as promising DMOAD candidates, their clinical application is hindered by inconsistent in vivo efficacy and an incomplete understanding of the underlying pathological mechanisms and therapeutic targets. Methods: To address these limitations, we developed a novel therapeutic strategy by conjugating MSCs with steroid-loaded gold nanostars (MSC-Au-Steroid). The effects of MSC-Au-Steroid were assessed in vitro using osteoarthritis patient-derived chondrocytes and peripheral blood mononuclear cells (PBMCs), and in vivo using a monosodium iodoacetate (MIA)-induced mouse model of osteoarthritis. Key assessments included anti-inflammatory activity, metabolic profiling (glycolysis and oxidative phosphorylation), mitochondrial function, reactive oxygen species (ROS) production, mTOR signaling, and immunomodulatory effects on Th1, Th17, and regulatory T cells (Tregs). Results: MSC-Au-Steroid demonstrated strong anti-inflammatory effects in OA chondrocytes, promoted cartilage regeneration, and normalized altered metabolic profiles under inflammatory conditions. It improved mitochondrial function and suppressed excessive ROS production via mTOR signaling regulation. In vivo ,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ChondrocytesMesenchymal Stem CellsAnimalsMice, Inbred C57BLHumansMiceOsteoarthritisDisease Models, AnimalGoldReactive Oxygen Species

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research